{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05515185",
      "orgStudyIdInfo": {
        "id": "KT095"
      },
      "organization": {
        "fullName": "The First People's Hospital of Lianyungang",
        "class": "OTHER"
      },
      "briefTitle": "B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors",
      "officialTitle": "An Open, Single-arm Clinical Study of Autologous T Cells (CAR-T) Targeting B7-H3 Chimeric Antigen Receptor Gene in the Treatment of Patients With Advanced Gastrointestinal Tumors"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-08",
      "overallStatus": "UNKNOWN",
      "lastKnownStatus": "NOT_YET_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2022-09-09",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-09-08",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2024-09-08",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2022-08-23",
      "studyFirstSubmitQcDate": "2022-08-23",
      "studyFirstPostDateStruct": {
        "date": "2022-08-25",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-08-23",
      "lastUpdatePostDateStruct": {
        "date": "2022-08-25",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "The First People's Hospital of Lianyungang",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.",
      "detailedDescription": "This is a single-center, single-arm, open-label study. This study is planned to enroll about 30 subjects with advanced solid tumors. Autologous CAR-T cells were then infused intravenously into subjects, in a dose-escalating 3+3 design."
    },
    "conditionsModule": {
      "conditions": [
        "Advanced Solid Tumor"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 30,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "KT095 CAR-T",
          "type": "EXPERIMENTAL",
          "description": "KT095 CAR-T injection Intravenous infusion",
          "interventionNames": [
            "Drug: KT095 CAR-T injection"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "KT095 CAR-T injection",
          "description": "Clearance of lymphocytes",
          "armGroupLabels": [
            "KT095 CAR-T"
          ],
          "otherNames": [
            "Fludarabine",
            "Cyclophosphamide"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Dose-limiting toxicity",
          "description": "DLT",
          "timeFrame": "Up to 2 years"
        },
        {
          "measure": "Maximum tolerable dose",
          "description": "MTD",
          "timeFrame": "Up to 2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Aged 18-70 and of both sexes;\n2. Advanced solid tumor diagnosed by histology or pathology;\n3. Relapse after receiving chemotherapy or targeted drugs or other second-line therapy;\n4. B7H3 antigen was positive in tumor tissues by immunohistochemistry, and the antigen expression rate was more than 15%.\n5. Patients had at least one evaluable tumor lesion according to RECIST 1.1 criteria that could be accurately measured at baseline;\n6. The ECOG score is 0-2, and the expected survival time is more than 12 weeks;\n7. Laboratory test results should at least meet the following requirements:\n\n   Left ventricular ejection fraction ≥40%; Creatinine ≤200 umol/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelet (PLT) ≥80×109/L; Hemoglobin ≥80g/L; Oxygen saturation of blood 91%; Total bilirubin ≤2×ULN; ALT and AST 2.5 x ULN or less; The criteria for abnormal ALT and AST due to disease (e.g., liver metastases or bile duct obstruction) or Gilbert syndrome can be relaxed to ≤5×ULN.\n8. Having venous access for blood collection or single blood collection;\n9. The patient voluntarily participated and signed the informed consent in person.\n\nExclusion Criteria:\n\n1. pregnant or lactating women;\n2. Chemotherapy or radiotherapy was used within 3 days before the blood collection period;\n3. Patients who have used systemic steroids within 5 days before blood collection period (except those who have recently or currently used inhaled steroids);\n4. Use drugs to stimulate bone marrow hematopoietic cell formation within 5 days before the blood collection period;\n5. Those who have used any gene or cell therapy products;\n6. History of epilepsy or other central nervous system diseases;\n7. Active hepatitis B or C virus, defined as: hepatitis B surface antigen HBsAg or hepatitis B core antibody HBcAb positive subjects with peripheral blood HBV DNA titer above the detection limit; HCV antibody positive for hepatitis C and HCV RNA positive in peripheral blood; People infected with HIV and syphilis;\n8. Other tumors in the past 5 years;\n9. Patients with severe chest and ascites;\n10. There was active or uncontrollable infection requiring systemic treatment within 14 days before enrollment;\n11. Other antineoplastic treatments (other than pretreatment and chemotherapy) were administered within 2 weeks before study initiation;\n12. The investigator assessed that the patient was unable or unwilling to comply with the protocol.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "70 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "xiaodong jiang, PhD",
          "role": "CONTACT",
          "phone": "0518-85767557",
          "email": "irb_lygyyy@163.com"
        }
      ],
      "locations": [
        {
          "facility": "Lianyungang First People's Hospital",
          "city": "Lianyungang",
          "state": "Jiangsu",
          "zip": "222000",
          "country": "China",
          "contacts": [
            {
              "name": "yi zhu, PhD",
              "role": "CONTACT",
              "phone": "13871188115",
              "email": "zhuyi@cart-med.com"
            }
          ],
          "geoPoint": {
            "lat": 34.59845,
            "lon": 119.21556
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-13"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C024352",
          "term": "fludarabine"
        },
        {
          "id": "D003520",
          "term": "Cyclophosphamide"
        }
      ],
      "ancestors": [
        {
          "id": "D010752",
          "term": "Phosphoramide Mustards"
        },
        {
          "id": "D009588",
          "term": "Nitrogen Mustard Compounds"
        },
        {
          "id": "D009150",
          "term": "Mustard Compounds"
        },
        {
          "id": "D006846",
          "term": "Hydrocarbons, Halogenated"
        },
        {
          "id": "D006838",
          "term": "Hydrocarbons"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D063088",
          "term": "Phosphoramides"
        },
        {
          "id": "D009943",
          "term": "Organophosphorus Compounds"
        }
      ]
    }
  },
  "hasResults": false
}